Skip to main content

Table 1 Demographic and clinical characteristics of HIV infected adults experiencing virologic failure

From: Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda

Characteristics Overall Not switched Switched
  n(%) n(%) n(%)
Population 124 42(34%) 82(66%)
Age in years
 18–24 14(11%) 3(7%) 11(13%)
 25–34 66(53%) 18(43%) 48(59%)
  ≥ 35 44(35%) 21(50%) 23(28%)
Gender
 Female 75(60%) 23(55%) 52(63%)
 Male 49(40%) 19(45%) 30(37%)
Year of ART Initiation
 2004–2007 78(63%) 26(62%) 52(63%)
 2008–2011 46(37%) 16(38%) 30(37%)
Type of ART treatment Clinic
 Central Clinic 23(19%) 7(17%) 16(20%)
 Peripheral clinic 101(81%) 35(83%) 66(80%)
WHO Stage
 1 34(27%) 10(24%) 24(29%)
 2 50(40%) 17(40%) 33(40%)
 3 or 4 40(32%) 15(36%) 25(30%)
First Line ART regimen
 EFV based regimen 36(29%) 14(33%) 22(27%)
 NVP based regimen 88(71%) 28(67%) 60(73%)
CD4 count at ART initiation (cells/ul)
  ≥ 100 78(63%) 33(79%) 45(55%)
  ≤ 99 46(37%) 9(21%) 37(45%)
CD4 count at ART failure (cells/ul)a
  ≥ 100 92(91%) 32(94%) 60(90%)
  ≤ 99 9(9%) 2(6%) 7(10%)
viral load at ART failure (cells/ul)
  ≤ 5000 33(27%) 18(43%) 15(18%)
 5001–10,000 19(15%) 6(14%) 13(16%)
  > 10,000 72(58%) 18(43%) 54(66%)
Year of virologic failure
 2005–2007 37(30%) 11(26%) 26(32%)
 2008–2013 87(70%) 31(74%) 56(68%)
Virologic suppression prior to virologic failure
 No 57(46%) 17(40%) 40(49%)
 Yes 67(54%) 25(60%) 42(51%)
Time from ART start to virologic failure
 0–12 months 36(29%) 14(33%) 22(27%)
 13–24 months 56(45%) 14(33%) 42(51%)
 25–36 months 23(19%) 8(19%) 15(18%)
  ≥ 37 months 9(7%) 6(14%) 3(4%)
Time from virologic failure to Switch (months)
 0–6 months N/A N/A 36(44%)
 7–12 months N/A N/A 16(20%)
 13–24 months N/A N/A 19(23%)
  ≥ 25 months N/A N/A 11(13%)
  1. a33 patients did not have CD4 at time of confirmed virologic failure; EFV Efavirenz, NVP Nevirapine